Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
1 clinical trials · Condition
◉ Watch Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
| Record | Firm | Date |
|---|---|---|
| Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies (NCT00825487) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2009-08-01 |
Track Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.